Capricor Therapeutics Inc(CAPR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:59 PM ET (Korea 10/31 08:59)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.45 | Insider Own | 9.44% | Shs Outstand | 58.1M | Perf Week | 7.59% |
| Market Cap | 0.37B | Forward P/E | - | EPS next Y | 3.28% | Insider Trans | -1.79% | Shs Float | 52.6M | Perf Month | -28.64% |
| Enterprise Value | 0.22B | PEG | - | EPS next Q | -0.13 | Inst Own | 72.84% | Short Float | 37.72% | Perf Quarter | 51.9% |
| Income | -0.13B | P/S | - | EPS this Y | 33.05% | Inst Trans | 13.65% | Short Ratio | 3.13 | Perf Half Y | -79.36% |
| Sales | 0.00B | P/B | 1.51 | EPS next 5Y | - | ROA | -51.53% | Short Interest | 19.86M | Perf YTD | -77.89% |
| Book/sh | 4.24 | P/C | 1.56 | EPS past 3/5Y | -24.12% -20.84% | ROE | -73.7% | 52W High | -84.2% ($40.37) | Perf Year | 2.74% |
| Cash/sh | 4.09 | P/FCF | - | Sales past 3/5Y | - | ROIC | -38.54% | 52W Low | 115.54% ($2.96) | Perf 3Y | 130.32% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -49.28% | Gross Margin | - | Volatility(W/M) | 8.08% 8.25% | Perf 5Y | 71.51% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.62 | Perf 10Y | -80.37% |
| Dividend Ex-Date | - | Quick Ratio | 7.35 | EPS Q/Q | -24.04% | Profit Margin | - | RSI (14) | 41.54 | Recom | 2.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.35 | Sales Q/Q | - | SMA20 | -6.64% ($6.83) | Beta | 0.73 | Target Price | $33.56 |
| Payout | - | Debt/Eq | 0.37 | Earnings | 2026/8/13 | SMA50 | -20.81% ($8.06) | Rel Volume | 0.46 | Prev Close | $6.63 |
| Employees | 231 | LT Debt/Eq | 0.36 | EPS/Sales Surpr. | -18.87% - | SMA200 | -69.28% ($20.77) | Avg Volume(3M) | 6.34M | Price | $6.38 |
| IPO | 2002/6/20 | Option/Short | Yes/Yes | Trades | 14218 | Volume | 2,912,893 | Change | -3.77% |
🧬 This is a US-based clinical-stage biotech company developing cell therapies and exosome-based therapeutics. It leverages cell-based treatment technology to develop therapies targeting conditions such as cardiac diseases associated with muscular dystrophy, and also maintains an exosome-based treatment platform. As a biotech entering the unmet disease market through a differentiated cell therapy approach, it offers a unique investment angle in the space.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded less than usual. That is 46% of its average volume.
CAPR has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +33.0% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +71.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
37.7% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #244 of 595 in the industry
Based on market cap of $371M.
RZLT#242 Rezolute Inc $382M PER - 
TRXB#243 Trex Bio Inc $377M PER - CAPR#244 Capricor Therapeutics Inc $371M PER - 
AGMB#245 AgomAb Therapeutics NV ADR $369M PER - 
FENC#246 Fennec Pharmaceuticals Inc $359M PER - 
FAQ
What kind of company is CAPR?
CAPR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CAPR?
The market cap of CAPR is approximately $371M, ranking 3,397 within its sector.
What is the 52-week high and low for CAPR?
CAPR has recorded a 52-week high of $40.37 and a low of $2.96.
